Articles

The Analytical Scientist publishes “In My View” By Jeff Zonderman of RedShiftBio.
Infrared spectroscopy is a useful technique for higher order structure analysis in the biopharmaceutical industry, but conventional systems lack pace and performance. It’s time for microfluidic modulation spectroscopy.

Biopharm International publishes a peer reviewed paper co-authored by Higher Order Structure group at Amgen.

Karen Steward from Technology Networks Interviews Julien Bradley on MMS.

RedShiftBio contributes towards Biosimilars feaure titled Biosimilars Tackle Interchangeability Standards in Biopharm International.

Genetic Engineering News publishes co authored article with RedShiftBio and Pressure BioSciences titled To Improve Protein Aggregation Assessments, Combine PCT and MMS.

Instrument Business Outlook interviews RedShiftBio CEO Julien Bradley on his new appointment.

A team led by researchers at the University of Washington has developed synthetic peptides that target and inhibit the small, toxic protein aggregates that are thought to trigger Alzheimer’s disease.

With the requirements of formulation development of biopharmaceuticals becoming more demanding, the evolution of analytical tools that can measure stability over a wide concentration range, in the presence of complex buffer systems is critical. Read this article in Drug Developmnet & Delivery to understand more about the role that MMS plays in formulation development.

Spectroscopy North America publishes peer-reviewed paper on MMS from Brent Kendrick of Elion Labs, Eugene Ma and Libo Wang of RedShiftBio.

Instrument Business Outlook interviews RedShiftBio CCO Jeff Zonderman on the launch of the AQS³pro.